Abraxane

Neoplasm Metastasis, refractory Testicular germ cell cancer, advanced Thymoma + 19 more
Treatment
6 FDA approvals
20 Active Studies for Abraxane

What is Abraxane

PaclitaxelThe Generic name of this drug
Treatment SummaryPaclitaxel, sold under the brand name Taxol, is a chemotherapy drug used to treat various cancers. It was first discovered in the bark of the Pacific yew tree in 1971 and is available as an intravenous solution or the newer formulation Abraxane, which contains albumin-bound paclitaxel. Paclitaxel works by inhibiting cell growth and division, preventing cancer cells from multiplying.
Paclitaxelis the brand name
image of different drug pills on a surface
Abraxane Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Paclitaxel
Paclitaxel
2001
60

Approved as Treatment by the FDA

Paclitaxel, also known as Paclitaxel, is approved by the FDA for 6 uses which include Non-Small Cell Lung Cancer and Neoplasm Metastasis .
Non-Small Cell Lung Cancer
Used to treat Non-Small Cell Lung Carcinoma (NSCLC) in combination with Cisplatin
Neoplasm Metastasis
Used to treat Pancreatic Adenocarcinoma Metastatic in combination with Gemcitabine
Malignant Neoplasms
Used to treat Metastatic Non-Small Cell Lung Cancer in combination with Carboplatin
Locally Advanced Non-Small Cell Lung Cancer
Used to treat Locally Advanced Non-Small Cell Lung Cancer in combination with Carboplatin
Advanced Ovarian Cancer
Used to treat Advanced Ovarian Cancer in combination with Cisplatin
Metastatic Breast Cancer

Effectiveness

How Abraxane Affects PatientsPaclitaxel is an antineoplastic agent typically used to treat ovarian cancer, breast cancer, and other types of cancer. Paclitaxel works by forming and stabilizing microtubules in cells, which stops the normal reorganization of microtubules that are needed for cell functions. This can lead to the formation of abnormal microtubule structures during cell division.
How Abraxane works in the bodyPaclitaxel disrupts the normal functioning of microtubules, which are an important part of a cell's structure. Paclitaxel binds to the beta subunit of tubulin, which makes up microtubules, and prevents them from disassembling. This makes it difficult for the cell to move molecules around, which is essential for cell functioning. Paclitaxel also binds to a protein called Bcl-2, which stops programmed cell death, and prevents it from working. This leads to cell death in cancer cells.

When to interrupt dosage

The portion of Abraxane is contingent upon the determined condition, including advanced Soft Tissue Sarcoma (STS), Malignant Neoplasms and Ovarian Cancer. The measure of dosage can be found in the table below, depending on the method of delivery (e.g. Liquid - Intravenous or Injection, solution - Intravenous).
Condition
Dosage
Administration
Neoplasm Metastasis
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Non-Small Cell Lung Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
advanced Thymoma
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Metastatic Bladder Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Metastatic Breast Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Acquired Immunodeficiency Syndrome
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Advanced Ovarian Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Advanced Head and Neck Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Small cell carcinoma of lung
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
refractory Testicular germ cell cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Locally Advanced Non-Small Cell Lung Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Neoplasm Metastasis
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
advanced Soft Tissue Sarcoma (STS)
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Kaposi Sarcoma
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Ovarian Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Ovarian Cancer
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Metastatic Melanoma
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Malignant Peritoneal Neoplasm
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Malignant Neoplasms
, 10.0 mg/mL, 30.0 mg/mL, 6.0 mg/mL, 100.0 mg, 5.0 mg/mL, 60.0 mg
, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Solution, Solution - Intravenous, Powder, for suspension, Powder, for suspension - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, for suspension, Injection, powder, for suspension - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Abraxane Contraindications
Condition
Risk Level
Notes
neutrophil count <1500 cells/mm3
Do Not Combine
neutrophil count <1000 cells/mm3
Do Not Combine
There are 20 known major drug interactions with Abraxane.
Common Abraxane Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Paclitaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Paclitaxel.
Abetimus
Major
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Paclitaxel.
Abraxane Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats is 32530 micrograms per kilogram. Overdosing on this drug may lead to reduced bone marrow function, nerve damage, and inflammation of the mucous membranes. In children, overdosing may be related to alcohol poisoning.
image of a doctor in a lab doing drug, clinical research

Abraxane Novel Uses: Which Conditions Have a Clinical Trial Featuring Abraxane?

Currently, 992 active studies are being conducted to assess the potential of Abraxane to manage Ovarian Cancer, Advanced Cervical Cancer and Kaposi Sarcoma.
Condition
Clinical Trials
Trial Phases
Advance Directives
0 Actively Recruiting
Ovarian Cancer
60 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Metastatic Breast Cancer
93 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Ovarian Cancer
224 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1
Metastatic Melanoma
94 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
Stomach Cancer
124 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
Advanced Cervical Cancer
0 Actively Recruiting
Advanced Ovarian Cancer
14 Actively Recruiting
Phase 3, Early Phase 1, Phase 2, Phase 1, Not Applicable
refractory Testicular germ cell cancer
0 Actively Recruiting
Malignant Neoplasms
12 Actively Recruiting
Phase 3, Phase 1, Phase 2
Kaposi Sarcoma
9 Actively Recruiting
Phase 1, Phase 2
Malignant Peritoneal Neoplasm
22 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
advanced Thymoma
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
5 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable
Metastatic Bladder Cancer
2 Actively Recruiting
Phase 2, Phase 1
Locally Advanced Non-Small Cell Lung Cancer
13 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Non-Small Cell Lung Cancer
348 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Advanced Head and Neck Cancer
1 Actively Recruiting
Phase 2
Small cell carcinoma of lung
1 Actively Recruiting
Phase 1

Abraxane Reviews: What are patients saying about Abraxane?

5Patient Review
1/3/2014
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I have had great results from this treatment. My hair is thinning, but that's the only downside so far. I'm finishing my third round (3 weeks on/1 off) and the tumors in my breast have reduced to 1/4 their size, the lung lesions are reducing, and the IBC is significantly reduced and not visible.
5Patient Review
5/31/2021
Abraxane for HR negative, HER2 negative, PD-L1 positive breast cancer
The tumor shrank so much that it could only be seen with an ultrasound. I also experienced light nausea, hair growth, and neuropathy in my fingers and around my mouth.
4.3Patient Review
10/6/2012
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I've experienced a significant reduction in my pain, ringing in my ears, and sinus problems since starting this treatment.
4Patient Review
8/26/2013
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I have experienced some nausea, extreme fatigue, and numbing in my lips and lower face. My cancer markers have gone up but I've only been on the drug for 1 month.
4Patient Review
9/16/2015
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I just completed my 10th round of treatment, and I'm feeling much better. The side effects are manageable, and the benefits have been significant according to my PET scan.
4Patient Review
3/13/2014
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I've had fifteen rounds of abraxane and found that it was very well-tolerated. The only side effect I experienced was thinning hair. However, my cancer antigen numbers have been steadily increasing, so my doctor is switching me to a different chemotherapy treatment.
4Patient Review
1/28/2015
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I received this treatment for six months, mostly in three-week intervals with one week off. I started to experience numbness and pain in my fingers and toes, which showed up on a CT scan as increased lesions in my liver. I'm now switching to eribulin.
3.7Patient Review
9/4/2014
Abraxane for Breast Cancer that has Spread to Another Part of the Body
So far, I've had this treatment every other Friday for six weeks. The most notable side effects have been some fatigue and hair loss (though not complete baldness, thankfully). The steroids given before the IV tend to cause insomnia that night. As for how well it's working...I can't say yet. We'll need to do more scans and tests down the road to be sure.
3.3Patient Review
5/14/2013
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I was having some serious abdominal pain and this medication really helped.
3Patient Review
5/3/2014
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I'm starting this treatment and will update my review later.
3Patient Review
11/5/2019
Abraxane for Breast Cancer that has Spread to Another Part of the Body
I just completed one session of Herceptin and Abraxane, as well as one session of Abraxane. I developed hives/rashes on my wrist, shoulder, neck and back afterwards. My dermatologist prescribed me claritin and triamcinolone, but the itching continues. Has anyone else experienced this side effect?
2.3Patient Review
11/15/2013
Abraxane for Non-Small Cell Lung Cancer
My husband was almost able to make it through two cycles, but the side effects were so severe that he had to stop. His white blood count went perilously low and he suffered from fatigue, hair loss, aches in his legs and feet, nausea, and stomach cramps. I thought this would be a good treatment for him, but I was wrong. He'll be getting a scan next week.
1.7Patient Review
8/10/2014
Abraxane for Breast Cancer that has Spread to Another Part of the Body
My mom is on her second round of this treatment, and she's still experiencing a lot of bone pain. She wasn't given a steroid the first time because she developed mouth sores and skin sores, so we're hoping this will be more effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about abraxane

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Taxol and Abraxane?

"Abraxane is a different form of paclitaxel than Taxol, they are both taxanes however Taxol uses a solvent called Cremophor EL to dissolve its main ingredients so the medicine can enter the bloodstream."

Answered by AI

What does Abraxane do to cancer?

"ABRAXANE works by inhibiting the function of microtubules, which are proteins that help cells divide. It is a systemic treatment, which means it is used to treat cancer that has spread to other parts of the body."

Answered by AI

What is Abraxane used for?

"metastatic melanoma

Nab-paclitaxel is a chemotherapy drug that is also known by its brand name, Abraxane. It combines the chemotherapy drug paclitaxel with a protein called albumin. It is a treatment for breast cancer that has spread and metastatic melanoma."

Answered by AI

Do you lose your hair with Abraxane?

"Some of the more common side effects that have been reported with ABRAXANE include hair loss, numbness and tingling in the extremities, and pain or weakness in the hands or feet."

Answered by AI

Clinical Trials for Abraxane

Have you considered Abraxane clinical trials? We made a collection of clinical trials featuring Abraxane, we think they might fit your search criteria.
Have you considered Abraxane clinical trials? We made a collection of clinical trials featuring Abraxane, we think they might fit your search criteria.
Have you considered Abraxane clinical trials? We made a collection of clinical trials featuring Abraxane, we think they might fit your search criteria.